论文部分内容阅读
目的:探讨持续低效每日血液透析滤过(SLEDD-f)对尿毒症脑病患者的疗效和安全性。方法:46例尿毒症脑病患者,分为SLEDD-f及连续性静脉静脉血液滤过(CVVH)/连续性动脉静脉血液滤过(CAVH)两组(各23例)进行治疗。比较两组治疗前后:APACHEⅡ评分、Glasgow评分、心率、MAP、血尿素氮、血清肌酐等变化。结果:两组治疗前后的心率、MAP等指标无显著差异(P>0.05)。两组治疗前后的血肌酐、尿素氮、APACHEⅡ评分及Glasgow评分指标有显著改善(P<0.05);但两组间上述指标变化值的差异无统计学意义(P>0.05)。讨论:对于尿毒症脑病患者,SLEDD-f和CVVH/CAVH均为安全且有效的治疗措施。
Objective: To investigate the efficacy and safety of continuous low-efficiency daily hemodiafiltration (SLEDD-f) in patients with uremic encephalopathy. Methods: Forty-six patients with uremic encephalopathy were divided into two groups (each 23 cases) with SLEDD-f and continuous venous venous hemofiltration (CVVH) / continuous arterial venous hemofiltration (CAVH). The changes of APACHEⅡscore, Glasgow score, heart rate, MAP, blood urea nitrogen and serum creatinine were compared between the two groups before and after treatment. Results: There was no significant difference in heart rate, MAP before and after treatment between the two groups (P> 0.05). Serum creatinine, urea nitrogen, APACHEⅡscore and Glasgow score were significantly improved in both groups before and after treatment (P <0.05). However, there was no significant difference between the two groups (P> 0.05). Discussion: SLEDD-f and CVVH / CAVH are safe and effective treatments for patients with uremic encephalopathy.